Company profile: Cadent Therapeutics
1.1 - Company Overview
Company description
- Provider of novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease, leveraging a precision neuroscience approach combining target specificity, patient selection, and drug design and optimization.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cadent Therapeutics
Vyripharm Bio
HQ: United States
Website
- Description: Provider of biotechnology research, personalized medicine and drug development services; the BioSync Platform for data management and evaluation integrating agribiopharmaceuticals with biopharmaceuticals and biotechnology; diagnostic and therapeutic imaging/treatment for image-guided therapy in infectious diseases, cancer and neurological disorders; VpH regulatory testing; a theranostic approach for viral infections; and VYR-206 for neurological outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vyripharm Bio company profile →
Predix Pharmaceuticals
HQ: United States
Website
- Description: Provider of drug discovery and development leveraging a novel 3D Discovery and Optimization Engine for GPCR drug candidates. Utilizes the proprietary PREDICT algorithm to computer-model the 3D structure of any GPCR target and advance novel compounds into the clinic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Predix Pharmaceuticals company profile →
Cannevert Therapeutics
HQ: Canada
Website
- Description: Provider of biopharma research and practical applications of cannabis in therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cannevert Therapeutics company profile →
Contineum Therapeutics
HQ: United States
Website
- Description: Provider of novel oral small molecule therapies for neuroscience, inflammation, and immunology, including PIPE-791, an LPA1R antagonist in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective M1 receptor inhibitor in development for relapsing-remitting multiple sclerosis (RRMS) and depression; and LPA1R DC, a peripherally restricted LPA1R antagonist.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Contineum Therapeutics company profile →
MAP Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel inhalation therapies under development for respiratory and systemic diseases, with proprietary product candidates including Unit Dose Budesonide for pediatric asthma (children six months to eight years) and MAP0004 for migraine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MAP Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cadent Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cadent Therapeutics
2.2 - Growth funds investing in similar companies to Cadent Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cadent Therapeutics
4.2 - Public trading comparable groups for Cadent Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →